Nuvectis Pharma Q3 net loss widens on milestone expenses

Nuvectis Pharma

04/11/2025 13:24

Overview

Nuvectis Pharma Q3 net loss widens to $7.5 mln due to milestone expenses

Cash position increased to $35.4 mln, supporting operations into Q3-2027

NXP900 Phase 1b program initiated, focusing on advanced cancers

Outlook

Nuvectis expects cash reserves to support operations into 3Q-2027

Company plans to initiate NXP900 combination therapy component by year-end

Nuvectis aims to achieve key milestones for NXP900 Phase 1b program

Result Drivers

MILESTONE EXPENSES - Increase in net loss due to a one-time $2.0 mln milestone achievement expense for NXP900

CASH POSITION - Cash and cash equivalents were $35.4 million as of September 30, 2025, compared to $18.5 million as of December 31, 2024

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
-$0.44
Q3 Operating Income
-$7.79 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Nuvectis Pharma Inc is $18.50, about 65.6% above its November 3 closing price of $6.36

Press Release: ID:nGNX2L9ZkC

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)